Literature DB >> 33962311

1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors.

Maria Chiara Pismataro1, Tommaso Felicetti1, Chiara Bertagnin2, Maria Giulia Nizi1, Anna Bonomini2, Maria Letizia Barreca1, Violetta Cecchetti1, Dirk Jochmans3, Steven De Jonghe3, Johan Neyts3, Arianna Loregian2, Oriana Tabarrini1, Serena Massari4.   

Abstract

In the search for new anti-influenza virus (IV) compounds, we have identified the 1,2,4-triazolo[1,5-a]pyrimidine (TZP) as a very suitable scaffold to obtain compounds able to disrupt IV RNA-dependent RNA polymerase (RdRP) PA-PB1 subunits heterodimerization. In this work, in order to acquire further SAR insights for this class of compounds and identify more potent derivatives, we designed and synthesized additional series of analogues to investigate the role of the substituents around the TZP core. To this aim, we developed four facile and efficient one-step procedures for the synthesis of 5-phenyl-, 6-phenyl- and 7-phenyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidines, and 2-amino-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol. Two analogues having the ethyl carboxylate moiety at the C-2 position of the TZP were also prepared in good yields. Then, the scaffolds herein synthesized and two previous scaffolds were functionalized and evaluated for their anti-IAV activity, leading to the identification of compound 22 that showed both anti-PA-PB1 (IC50 = 19.5 μM) and anti-IAV activity (EC50 = 16 μM) at non-toxic concentrations, thus resulting among the most active TZP derivatives reported to date by us. A selection of the synthesized compounds, along with a set of in-house available analogues, was also tested against SARS-CoV-2. The most promising compound 49 from this series displayed an EC50 value of 34.47 μM, highlighting the potential of the TPZ scaffold in the search for anti-CoV agents.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  1,2,4-triazolo[1,5-a]pyrimidines; Antiviral agents; Influenza polymerase; Influenza virus; PA-PB1 interaction; Protein-protein interaction; SARS-CoV-2

Year:  2021        PMID: 33962311     DOI: 10.1016/j.ejmech.2021.113494

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Gene Expression Profile Analysis of Human Epidermal Keratinocytes Expressing Human Papillomavirus Type 8 E7.

Authors:  Xianzhen Chen; Ma Li; Yi Tang; Qichang Liang; Chunting Hua; Huiqin He; Yinjing Song; Hao Cheng
Journal:  Pathol Oncol Res       Date:  2022-05-18       Impact factor: 2.874

Review 2.  Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins.

Authors:  Lingxin Hou; Ying Zhang; Han Ju; Srinivasulu Cherukupalli; Ruifang Jia; Jian Zhang; Bing Huang; Arianna Loregian; Xinyong Liu; Peng Zhan
Journal:  Acta Pharm Sin B       Date:  2021-11-19       Impact factor: 14.903

3.  Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant.

Authors:  Ruifang Jia; Jiwei Zhang; Jian Zhang; Chiara Bertagnin; Anna Bonomini; Laura Guizzo; Zhen Gao; Xiangkai Ji; Zhuo Li; Chuanfeng Liu; Han Ju; Xiuli Ma; Arianna Loregian; Bing Huang; Peng Zhan; Xinyong Liu
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.